Merck’s Opdivo is the first I-O therapy to be approved in China

China’s Drug Administration has approved Opdivo, the country’s first immuno-oncology and the first PD-1—therapy. 

The drug’s developer, Bristol-Myers Squibb, won’t be celebrating long as there are other therapies to come including Merck’s Ketruda.

Opdivo goes directly to the larger and more lucrative lung cancer market with this Chinese approval, for patients with previously chemo-treated advanced non-small cell lung cancer to be exact.

China’s most common form of cancer is Lung cancer with nearly 800,000 new diagnoses each year, based on official data from 2014. In comparison, the U.S. has less than one-third of that, or 234,000, according to the American Cancer Society’s estimate for 2018.

Click here to view the entire article.